Table 2. Numbers of papers with specific characteristics of dynamic transmission models by group among 83 papers with such models.
Characteristic KRI IC IDM Other
Transmission models 49 a,b [10, 27, 70] 4 [97–100] 5 [129, 132–135] 24 [147–171]
WPV, cVDPV, and/or OPV outbreaks (only) 1 [70] 3 [97–99] 1 [132] 9 [147, 148, 152, 157–159, 167–170]
WPV, cVDPV, and/or OPV transmission 11 a [10, 27] 1 [100] 3 [129, 134, 135] 13 [149–151, 154, 156, 160–166, 171]
All LPVs transmission and OPV evolution 37 b   1 [133] 2 [153, 155]
Models that include specific complexities
Seasonality 47 a,b [10]   1 [132] 4 [158, 160, 162, 163, 166]
Specific-serotype transmission model inputs 39 b [10, 27] 3 [98–100] 5 [129, 132–135] 5 [161, 162, 165, 166, 170]
OPV secondary spread 48 a,b [10, 27] 1 [100] 4 [129, 133–135] 8 [151, 153–155, 161, 165, 166, 170]
VAPP 46 a,b     1 [150]
Fecal-oral and oropharyngeal transmission separately 37 b      
Waning 46 a,b   3 [129, 134, 135] 3 [154, 163, 165]
Reinfection 46 a,b   3 [129, 134, 135] 3 [154, 163, 165]
Boosting of immunity by IPV 46 a,b   3 [134, 135]  
Multiple age groups 45 c 1 [98] 3 [129, 132, 134] 5 [149, 154, 158, 159, 165, 170]
Subpopulations 34 d   2 [129, 132] 4 [159, 160, 163, 164]
Heterogeneous preferential mixing between age groups 45 c 1 [98] 1 [132] 1 [159]
Heterogeneous preferential mixing between subpopulations 34 d   2 [132, 133] 2 [159, 163]
Models that include specific states
Different immunity states for OPV and IPV if model includes both 48 a,b [10, 27]     3 [153, 161, 163]
Multiple immunity states for immunity induced for different OPV and/or IPV dose histories 37 b   5 [129, 132–135] 1 [162]
Maternal antibodies in infants 37 b   5 [129, 132–135] 1 [158]
1 or more latent stages (infected not infectious) 48 a,b [10, 27] 3 [97–99]   9 [151, 152, 156, 159, 161–163, 166, 170]
Multi-stage infection processes 38 b [27]   5 [129, 132–135] 2 [151, 161]
Environmental reservoir       3 [149, 160, 171]
Vaccination considered
OPV in RI 48 a,b [10, 27] 1 [100] 5 [129, 132–135] 13 [150, 151, 153–157, 159, 161, 163–165, 171]
OPV in SIAs 45 b [10, 14, 18–20, 22, 24, 25] 2 [98, 100] 5 [129, 132–135] 8 [150, 151, 155, 159, 160, 162, 166, 170]
IPV in RI 38 b [10] 1 [97] 2 [133–135] 8 [150, 152, 153, 159, 161, 163, 164, 170]
IPV in SIAs 9 [51, 55, 59, 64, 68, 73–76]   1 [133] 1 [150]
Differences in OPV and IPV RI schedules 37 b   5 [129, 132–135]  
Repeatedly missed children in successive SIAs 37 b 1 [100]    
Abbreviations: cVDPV, circulating vaccine-derived poliovirus; IC, Imperial College; IDM, Institute for Disease Modeling; IPV, inactivated poliovirus vaccine; KRI, Kid Risk, Inc.; LPV, live poliovirus; OPV, oral poliovirus vaccine; RI, routine immunization; SIAs, supplementary immunization activities; VAPP, vaccine-associated paralytic polio; WPV, wild poliovirus.
a All of the following: [9, 14, 18–20, 22, 24–26].
b All of the following: [4, 33–36, 38–41, 43, 46, 47, 49–62, 64, 65, 68, 69, 71, 73–77, 81].
c All of the following: [4, 9, 10, 14, 18–20, 22, 24, 26, 33–36, 38–41, 43, 46, 47, 49–62, 64, 65, 68, 71, 73–77, 81].
d All of the following: [4, 10, 26, 35, 36, 40, 43, 46, 47, 49–62, 64, 65, 68, 69, 71, 73–77, 81].